HK Stock Market Move | ALEBUND-B(09637) rose nearly 8% in the afternoon as AP308/PKU308 received clinical trial authorization from the U.S. FDA.

ALEBUND-B(09637) rose nearly 8% in the afternoon. As of press time, it was up 5.72% at HK$24.78, with a turnover of HK$12.7144 million. On the news front, Peking University First Hospital recently announced that, based on its IgA protease candidate drug developed and successfully translated by the Department of Nephrology, it has jointly developed a next-generation AP308/PKU308 with Alebund Pharmaceuticals. The Investigational New Drug (IND) application for the treatment of IgA nephropathy (IgAN) has been approved by the U.S. Food and Drug Administration (FDA) and is about to enter the first-in-human clinical study stage. It is worth noting that, according to data from the Center for Drug Evaluation of the National Medical Products Administration, on September 28, the application for AP308 for injection by Shanghai Alebund Pharmaceuticals Technology Co., Ltd. was accepted, with the acceptance number CXSL2601066.